Hematologist Martin Tallman, seen here on teaching rounds, evaluates such factors as bone marrow biopsy results and overall health in diagnosing and treating myelodysplastic syndromes.
Memorial Sloan Kettering’s Hematology Disease Management Team provides comprehensive, multidisciplinary care to more than 100 new patients with myelodysplastic syndromes (MDS) each year.
Our doctors conduct clinical trials to evaluate the latest therapies, and lecture at major conferences and institutions around the world. In addition, Memorial Sloan Kettering has been designated a Center of Excellence by the Myelodysplastic Syndromes Foundation.
Learn about how Memorial Sloan Kettering physicians diagnose, classify, stage, and treat patients with MDS.
Proper diagnosis is crucial so that you receive the most-effective treatment for MDS. The disease is often not diagnosed until the patient is seen by a hematologist, and cannot be definitively diagnosed until a hematopathologist examines a bone marrow sample.
- Classification & Staging
After a diagnosis is made using the results of blood and bone marrow tests, the MDS subtype is determined using either the World Health Organization (WHO) classification system or the French-American-British (FAB) classification system.
At Memorial Sloan Kettering, treatment for MDS may include stem cell transplantation, supportive care, and a variety of other options that could be available through a clinical trial.